Table 2 Comparison of clinical findings between symptomatic and asymptomatic groups
| Â | Symptomatic group | Asymptomatic group | |
|---|---|---|---|
|  | n = 165 (%) | n = 47 (%) | p value |
Age (years) | Â | Â | Â |
Median (range) | 49 (21–82) | 64 (38–89) | < 0.001 |
Sex | Â | Â | 0.046 |
Male | 84 (50.9) | 32 (68.1) | Â |
Female | 81 (49.1) | 15 (31.9) | Â |
Comorbidities | Â | Â | Â |
Ischemic heart disease | 7 (4.2) | 3 (6.4) | 0.700 |
Liver cirrhosis | 0 (0.0) | 2 (4.3) | 0.048 |
Diabetes mellitus | 8 (3.8) | 7 (14.9) | 0.026 |
CKD with dialysis | 0 (0.0) | 1 (2.1) | 0.220 |
NSAIDs | 6 (3.6) | 1 (2.1) | 0.874 |
Acid secretion inhibitor | 25 (15.2) | 12 (25.5) | 0.126 |
Gastric mucosa | Â | Â | 0.001 |
No atrophy | 124 (75.2) | 21 (44.7) | Â |
Atrophy | 41 (24.8) | 26 (55.3) | Â |
Location | Â | Â | 0.386 |
Upper third | 57 (34.5) | 17 (36.2) | Â |
Middle third | 72 (43.6) | 24 (51.1) | Â |
Lower third | 36 (21.8) | 6 (12.8) | Â |
Circumference | Â | Â | 0.163 |
Anterior wall | 15 (9.1) | 10 (21.3) | Â |
Posterior wall | 28 (17.0) | 6 (12.8) | Â |
Greater curvature | 97 (58.8) | 26 (55.3) | Â |
Lesser curvature | 25 (15.2) | 5 (10.6) | Â |
Mucosa of penetrating area | Â | Â | 0.038 |
Atrophy | 28 (17.0) | 15 (31.9) | Â |
No atrophy | 137 (83.0) | 32 (68.1) | Â |
Edema, erythema, erosion | Â | Â | 0.429 |
Positive | 130 (78.8) | 34 (72.3) | Â |
Negative | 35 (21.2) | 13 (27.7) | Â |